当前位置: 首页 >> 检索结果
共有 7489 条符合本次的查询结果, 用时 4.0089268 秒

3361. Telomerase inhibition in haematological neoplasms-are we ready for primetime?

作者: Mrinal M Patnaik.
来源: Lancet. 2024年403卷10423期220-222页

3362. Health-worker education for disability inclusion in health.

作者: Luthfi Azizatunnisa.;Sara Rotenberg.;Tom Shakespeare.;Satendra Singh.;Tracey Smythe.
来源: Lancet. 2024年403卷10421期11-13页

3363. Improving survival from metastatic, recurrent, or persistent cervical cancer.

作者: Linda R Mileshkin.;Sathya Manoharan.
来源: Lancet. 2024年403卷10421期2-4页

3364. Conservative versus liberal oxygenation targets in critically ill children (Oxy-PICU): a UK multicentre, open, parallel-group, randomised clinical trial.

作者: Mark J Peters.;Doug W Gould.;Samiran Ray.;Karen Thomas.;Irene Chang.;Marzena Orzol.;Lauran O'Neill.;Rachel Agbeko.;Carly Au.;Elizabeth Draper.;Lee Elliot-Major.;Elisa Giallongo.;Gareth A L Jones.;Lamprini Lampro.;Jon Lillie.;Jon Pappachan.;Sam Peters.;Padmanabhan Ramnarayan.;Zia Sadique.;Kathryn M Rowan.;David A Harrison.;Paul R Mouncey.; .
来源: Lancet. 2024年403卷10424期355-364页
The optimal target for systemic oxygenation in critically ill children is unknown. Liberal oxygenation is widely practiced, but has been associated with harm in paediatric patients. We aimed to evaluate whether conservative oxygenation would reduce duration of organ support or incidence of death compared to standard care.

3365. Imetelstat in patients with lower-risk myelodysplastic syndromes who have relapsed or are refractory to erythropoiesis-stimulating agents (IMerge): a multinational, randomised, double-blind, placebo-controlled, phase 3 trial.

作者: Uwe Platzbecker.;Valeria Santini.;Pierre Fenaux.;Mikkael A Sekeres.;Michael R Savona.;Yazan F Madanat.;Maria Díez-Campelo.;David Valcárcel.;Thomas Illmer.;Anna Jonášová.;Petra Bělohlávková.;Laurie J Sherman.;Tymara Berry.;Souria Dougherty.;Sheetal Shah.;Qi Xia.;Libo Sun.;Ying Wan.;Fei Huang.;Annat Ikin.;Shyamala Navada.;Faye Feller.;Rami S Komrokji.;Amer M Zeidan.
来源: Lancet. 2024年403卷10423期249-260页
Unmet medical needs remain in patients with red blood cell transfusion-dependent (RBC-TD) lower-risk myelodysplastic syndromes (LR-MDS) who are not responding to or are ineligible for erythropoiesis-stimulating agents (ESAs). Imetelstat, a competitive telomerase inhibitor, showed promising results in a phase 2 trial. We aimed to compare the RBC transfusion independence (RBC-TI) rate with imetelstat versus placebo in patients with RBC-TD LR-MDS.

3366. State of the health-care system in Gaza during the Israel-Hamas war.

作者: Hussam Mahmoud.;Samer Abuzerr.
来源: Lancet. 2023年402卷10419期2294页

3367. Israel: LGBTQ+ activism, conflict dynamics, and global responses.

作者: Roy Zucker.
来源: Lancet. 2023年402卷10419期2292页

3368. Gaza, 9 years on: a humanitarian catastrophe.

作者: Ayesha Musa.;Jane Crawley.;Tanya Haj-Hassan.;Rebecca Inglis.;Nick Maynard.
来源: Lancet. 2023年402卷10419期2292-2293页

3369. Bruce Richman: building the U=U movement for HIV prevention.

作者: Tony Kirby.
来源: Lancet. 2024年403卷10421期18页

3370. HIV epidemiology, prevention, treatment, and implementation strategies for public health.

作者: Aaloke Mody.;Annette H Sohn.;Collins Iwuji.;Rayner K J Tan.;Francois Venter.;Elvin H Geng.
来源: Lancet. 2024年403卷10425期471-492页
The global HIV response has made tremendous progress but is entering a new phase with additional challenges. Scientific innovations have led to multiple safe, effective, and durable options for treatment and prevention, and long-acting formulations for 2-monthly and 6-monthly dosing are becoming available with even longer dosing intervals possible on the horizon. The scientific agenda for HIV cure and remission strategies is moving forward but faces uncertain thresholds for success and acceptability. Nonetheless, innovations in prevention and treatment have often failed to reach large segments of the global population (eg, key and marginalised populations), and these major disparities in access and uptake at multiple levels have caused progress to fall short of their potential to affect public health. Moving forward, sharper epidemiologic tools based on longitudinal, person-centred data are needed to more accurately characterise remaining gaps and guide continued progress against the HIV epidemic. We should also increase prioritisation of strategies that address socio-behavioural challenges and can lead to effective and equitable implementation of existing interventions with high levels of quality that better match individual needs. We review HIV epidemiologic trends; advances in HIV prevention, treatment, and care delivery; and discuss emerging challenges for ending the HIV epidemic over the next decade that are relevant for general practitioners and others involved in HIV care.

3371. Victims of gender-based violence on Oct 7 must be given a voice.

作者: Matthew Ari Fox.;Tamara Kolitz.
来源: Lancet. 2023年402卷10419期2290-2291页

3372. The cycling of self-care through history.

作者: Mandip Aujla.;Manjulaa Narasimhan.
来源: Lancet. 2023年402卷10417期2066-2067页

3373. Deaths from work-related illnesses are increasing.

作者: John Zarocostas.
来源: Lancet. 2023年402卷10417期2061页

3374. Palantir NHS contract raises criticisms.

作者: Jacqui Thornton.
来源: Lancet. 2023年402卷10417期2060页

3375. Argentine medics raise alarm after Milei election.

作者: Amy Booth.
来源: Lancet. 2023年402卷10417期2059页

3376. Intracoronary artery visualisation of crystalline sirolimus deposits after drug-coated balloon angioplasty for acute coronary syndrome.

作者: Víctor Alfonso Jiménez Díaz.;Andrés Íñiguez Romo.
来源: Lancet. 2023年402卷10417期2111-2112页

3379. Offline: China-how to rescue a nation and the world.

作者: Richard Horton.
来源: Lancet. 2023年402卷10417期2058页

3380. Non-communicable diseases in China: a rising tide.

作者: The Lancet.
来源: Lancet. 2023年402卷10417期2045页
共有 7489 条符合本次的查询结果, 用时 4.0089268 秒